Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Triple-negative breast cancer cell lines treated with mebedazole (an FDA-approved anti-parasitic).

ABSTRACT: Triple-negative breast cancer cell lines treated with mebedazole (an FDA-approved anti-parasitic).

PROVIDER: PRJNA788559 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17223257_1.fastq.gz	Fastqsanger.gz
	SRR17223257_2.fastq.gz	Fastqsanger.gz
	SRR17223258_1.fastq.gz	Fastqsanger.gz
	SRR17223258_2.fastq.gz	Fastqsanger.gz
	SRR17223259_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Triple-negative breast cancer cell lines treated with mebedazole (an FDA-approved anti-parasitic).

Project description:The main purpose of this project is to identify gene expression changes between treated triple negative breast cancer cells (w/ MBZ) vs. non-treated cells (w/o MBZ). We have submitted two different cell ilnes, and those overlapping pathways will be important to elucidate the mechansim of MBZ. Cell Lines = SM or MD Drug treatment = 0M or 1M

2022-02-28 | GSE190845 | GEO

Drug Repurposing Identifies Proteasome Inhibitors as Antiproliferative Agents Counteracting Inflammation-Driven Chemoresistance in Triple-Negative Breast Cancer Organoids

Project description:Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options, characterized by high relapse rates and poor survival outcomes due to chemoresistance. This study aimed to repurpose FDA-approved drugs to overcome chemoresistance in TNBC and elucidate their mechanisms of action.

2026-01-06 | PXD059504 | JPOST Repository

Breast cancer cell lines treated with mebedazole (an FDA-approved anti-parasitic) under 20% or 1% oxygen conditions.

Project description:Breast cancer cell lines treated with mebedazole (an FDA-approved anti-parasitic) under 20% or 1% oxygen conditions.

| PRJNA923234 | ENA

FDA-approved Disulfiram Inhibits the NLRP3 Inflammasome

Project description:The NLRP3 inflammasome is dysregulated in autoinflammatory disorders caused by inherited mutations and contributes to the pathogenesis of several chronic inflammatory diseases. In this study, we discovered that disulfiram, a safe FDA-approved drug, specifically inhibits the NLRP3 inflammasome, but not the NLRC4 or AIM2 inflammasomes. Disulfiram suppresses caspase-1 activation, ASC speck formation, and pyroptosis induced by several stimuli that activate NLRP3. Mechanistically, NLRP3 is palmitoylated at cysteine 126, a modification required for its localization to the trans-Golgi network and inflammasome activation which was inhibited by disulfiram. Administration of disulfiram to animals inhibited the NLRP3, but not the NLRC4 inflammasome in vivo. Our study uncovers a mechanism by which disulfiram targets NLRP3 and provides a rationale for using a safe FDA-approved drug for the treatment of NLRP3-associated inflammatory diseases.

2024-07-25 | PXD054126 | Pride

Transcriptome analysis of osteosarcoma cell lines treated with FDA-approved drugs

Project description:In order to understand the effect of FDA-approved drugs including doxorubicin (DOX) and HDACs inhibitors (PXD101 and PCI-24781) on osteosarcoma, 143B osteosarcoma cells were treated with the single agents or combinations of these drugs. Three biological replicates of each sample were processed for next-generation sequencing (NGS).

2025-12-31 | GSE218036 | GEO

Transcriptome analysis of osteosarcoma cell lines treated with FDA-approved drugs

Project description:Transcriptome analysis of osteosarcoma cell lines treated with FDA-approved drugs

| PRJNA901972 | ENA

Identification of FDA-Approved Drugs that Induce Heart Regeneration in Mammals

Project description:Identification of FDA-Approved Drugs that Induce Heart Regeneration in Mammals

| PRJNA1004155 | ENA

Identification of FDA-Approved Drugs that Induce Heart Regeneration in Mammals [ChIP]

Project description:Identification of FDA-Approved Drugs that Induce Heart Regeneration in Mammals [ChIP]

| PRJNA1003797 | ENA

Identification of FDA-Approved Drugs that Induce Heart Regeneration in Mammals [RNA]

Project description:Identification of FDA-Approved Drugs that Induce Heart Regeneration in Mammals [RNA]